# mRECIST — Modified RECIST for hepatocellular carcinoma

> Assesses HCC treatment response using viable (enhancing) tumor.

**Situação:** vigente · **Órgão:** Oncologia · **Órgão emissor:** Oncology imaging consensus · **Versão:** 2010 · **Ano:** 2010

## Procedência e vigência
- Família: léxico
- Tipo de lógica: flat
- Modalidade: CT, MRI
- Fonte primária: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma (2010) — https://doi.org/10.1055/s-0030-1247132
- Última verificação: 2026-06-26
- Última checagem: 2026-06-26

## Categorias

| Código | Rótulo | Critérios | Conduta | Risco | Localizador | Verificado |
| --- | --- | --- | --- | --- | --- | --- |
| CR | Complete response | Complete Response: disappearance of all arterially enhancing (viable) tumor tissue, i.e. loss of any intratumoral arterial-phase hyperenhancement across all target and non-target HCC lesions. | — | — | PMC5771991 (Voizard et al., 'Locoregional Therapies for Hepatocellular Carcinoma and the New LI-RADS Treatment Response Algorithm') Table 4 'Overview of Response Criteria and Categories', mRECIST row ('Disappearance of any intratumoral APHE in all target and non-target lesions'); cross-checked PMC4624170 'Evaluation of treatment response' ('absence of arterially enhanced areas in all target lesions') | ✓ |
| PR | Partial response | Partial Response: at least a 30% reduction in the sum of the diameters of the viable (arterially enhancing) portions of target lesions, referenced to the baseline sum. | — | — | PMC5771991 Table 4 mRECIST row ('>=30% decrease in the sum of diameters of viable target lesions'); reference is baseline per article text; cross-checked PMC4624170 'Evaluation of treatment response' ('>30% decrease' in sum of diameters of arterially enhanced areas vs baseline) | ✓ |
| SD | Stable disease | Stable Disease: viable enhancing tumor that shrinks too little to qualify as partial response and grows too little to qualify as progressive disease. | — | — | PMC5771991 Table 4 mRECIST row ('Any cases that do not qualify for either partial response or progressive disease'); cross-checked PMC4624170 'Evaluation of treatment response' ('Neither PR nor PD') | ✓ |
| PD | Progressive disease | Progressive Disease: at least a 20% increase in the sum of the diameters of viable (arterially enhancing) target lesions, or the appearance of one or more new lesions, or unequivocal progression of non-target disease. | — | — | PMC5771991 Table 4 mRECIST row ('>=20% increase in the sum of the diameters of viable target lesions or presence of one or more new lesions or unequivocal progression of existing non target lesions'); cross-checked PMC4624170 'Evaluation of treatment response' ('>20% increase' in sum of diameters of arterially enhanced areas) | ✓ |

### Citações por categoria
- **CR**: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma (2010) — https://doi.org/10.1055/s-0030-1247132 · PMC5771991 (Voizard et al., 'Locoregional Therapies for Hepatocellular Carcinoma and the New LI-RADS Treatment Response Algorithm') Table 4 'Overview of Response Criteria and Categories', mRECIST row ('Disappearance of any intratumoral APHE in all target and non-target lesions'); cross-checked PMC4624170 'Evaluation of treatment response' ('absence of arterially enhanced areas in all target lesions')
- **PR**: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma (2010) — https://doi.org/10.1055/s-0030-1247132 · PMC5771991 Table 4 mRECIST row ('>=30% decrease in the sum of diameters of viable target lesions'); reference is baseline per article text; cross-checked PMC4624170 'Evaluation of treatment response' ('>30% decrease' in sum of diameters of arterially enhanced areas vs baseline)
- **SD**: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma (2010) — https://doi.org/10.1055/s-0030-1247132 · PMC5771991 Table 4 mRECIST row ('Any cases that do not qualify for either partial response or progressive disease'); cross-checked PMC4624170 'Evaluation of treatment response' ('Neither PR nor PD')
- **PD**: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma (2010) — https://doi.org/10.1055/s-0030-1247132 · PMC5771991 Table 4 mRECIST row ('>=20% increase in the sum of the diameters of viable target lesions or presence of one or more new lesions or unequivocal progression of existing non target lesions'); cross-checked PMC4624170 'Evaluation of treatment response' ('>20% increase' in sum of diameters of arterially enhanced areas)

## Referências cruzadas
- _fronteira compartilhada_ → [RECIST 1.1 — Response Evaluation Criteria in Solid Tumours v1.1](https://radcommons.laudos.ai/systems/recist-1-1.md) — mRECIST adapts RECIST 1.1 to measure viable enhancing tumor in HCC.


---
> Conteúdo de referência reescrito. Confira a publicação primária vigente. Não é dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.

Página HTML: https://radcommons.laudos.ai/systems/mrecist · JSON da API: https://radcommons.laudos.ai/api/v1/systems/mrecist · Índice para agentes: https://radcommons.laudos.ai/llms.txt